Cargando…

Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy

BACKGROUND: Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor treatment for HER2-positive breast cancer have led to greater use of non-anthracyc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Anthony F., Dang, Chau T., Jorgensen, Justine, Moskowitz, Chaya S., DeFusco, Patricia, Oligino, Eric, Oeffinger, Kevin C., Liu, Jennifer E., Steingart, Richard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996968/ https://www.ncbi.nlm.nih.gov/pubmed/36895062 http://dx.doi.org/10.1186/s40959-023-00163-4

Ejemplares similares

Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
por: Yu, Anthony F., et al.
Publicado: (2020)

Predicting Adverse Health Outcomes in Long-Term Survivors of a Childhood Cancer
por: Moskowitz, Chaya S., et al.
Publicado: (2014)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging
por: Pun, Shawn C., et al.
Publicado: (2016)

Examining Cardiotoxicity With HER2 Therapies
por: Denduluri, Neelima
Publicado: (2020)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology
por: Steingart, Richard M., et al.
Publicado: (2019)

Benign and Malignant Findings on Chest CT Among Adult Survivors of Childhood and Young Adult Cancer with a History of Chest Radiotherapy
por: Barnea, Dana, et al.
Publicado: (2023)

Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer‐Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole‐Body Positron Emission Tomography
por: Chan, Angel T., et al.
Publicado: (2019)

Systems analysis of the effects of the 2014-16 Ebola crisis on WHO-reporting nations’ policy adaptations and 2020-21 COVID-19 response: a systematized review
por: Hanson-DeFusco, Jessi, et al.
Publicado: (2023)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
por: Jerusalem, Guy, et al.
Publicado: (2019)

Quantitative investment analysis
por: DeFusco, Richard, et al.
Publicado: (2007)

Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer
por: Chan, Angel T., et al.
Publicado: (2017)

Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies
por: Shamseddine, Achraf, et al.
Publicado: (2022)

Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?
por: Gherghe, Mirela, et al.
Publicado: (2022)

T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study
por: Dinan, Michaela, et al.
Publicado: (2022)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria
por: Zhu, Quing, et al.
Publicado: (2014)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
por: Ferdinandy, Péter, et al.
Publicado: (2019)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer
por: Guan, Jingyuan, et al.
Publicado: (2021)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Oncology professionals’ perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: A qualitative study
por: Koop, Yvonne, et al.
Publicado: (2021)

Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry)
por: Inoue, Keiko, et al.
Publicado: (2021)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021)

Rationale and Methods for the National Tuberculosis Genotyping and Surveillance Network
por: Castro, Kenneth G., et al.
Publicado: (2002)

Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance
por: Hills, Susan, et al.
Publicado: (2009)

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial
por: Iyengar, Neil M., et al.
Publicado: (2019)

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
por: Rahman, Atiar M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_2piv3tq0ev4vnif080g8go36ir